Hologic, Inc. (NASDAQ:HOLX) Given Average Rating of “Moderate Buy” by Brokerages

Hologic, Inc. (NASDAQ:HOLX) has earned a consensus recommendation of “Moderate Buy” from the eleven research firms that are presently covering the firm, Marketbeat reports. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $87.60.

A number of brokerages have recently commented on HOLX. JPMorgan Chase & Co. lifted their price target on shares of Hologic from $91.00 to $95.00 and gave the stock an “overweight” rating in a report on Tuesday, July 30th. Stephens reaffirmed an “overweight” rating and issued a $92.00 target price on shares of Hologic in a research note on Tuesday, July 30th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $82.00 price objective on shares of Hologic in a research report on Friday, August 16th. StockNews.com upgraded Hologic from a “buy” rating to a “strong-buy” rating in a research note on Tuesday. Finally, Needham & Company LLC reissued a “buy” rating and issued a $90.00 price target on shares of Hologic in a research note on Tuesday, July 30th.

Insider Activity at Hologic

In other Hologic news, Director Christiana Stamoulis sold 9,039 shares of the company’s stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $79.50, for a total transaction of $718,600.50. Following the completion of the sale, the director now directly owns 45,472 shares in the company, valued at $3,615,024. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, Director Christiana Stamoulis sold 9,039 shares of the stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $79.50, for a total value of $718,600.50. Following the completion of the sale, the director now owns 45,472 shares of the company’s stock, valued at $3,615,024. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Benjamin Jordan Cohn sold 5,093 shares of Hologic stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $81.99, for a total transaction of $417,575.07. Following the transaction, the insider now owns 10,476 shares in the company, valued at approximately $858,927.24. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 18,280 shares of company stock worth $1,469,973. 1.75% of the stock is owned by insiders.

Institutional Investors Weigh In On Hologic

A number of large investors have recently modified their holdings of the stock. Sanctuary Advisors LLC acquired a new position in Hologic during the 2nd quarter worth approximately $1,212,000. Quarry LP raised its stake in shares of Hologic by 323.7% during the second quarter. Quarry LP now owns 1,809 shares of the medical equipment provider’s stock valued at $134,000 after purchasing an additional 1,382 shares during the period. Sunbelt Securities Inc. acquired a new position in shares of Hologic during the second quarter worth $37,000. Creative Planning boosted its stake in shares of Hologic by 2.4% in the second quarter. Creative Planning now owns 21,813 shares of the medical equipment provider’s stock valued at $1,620,000 after purchasing an additional 503 shares during the period. Finally, Select Equity Group L.P. grew its holdings in Hologic by 87.6% during the 2nd quarter. Select Equity Group L.P. now owns 338,020 shares of the medical equipment provider’s stock valued at $25,098,000 after purchasing an additional 157,835 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Stock Performance

Hologic stock opened at $80.42 on Friday. Hologic has a fifty-two week low of $64.02 and a fifty-two week high of $84.67. The company has a market capitalization of $18.77 billion, a price-to-earnings ratio of 41.03, a PEG ratio of 2.58 and a beta of 0.98. The stock has a fifty day moving average of $80.06 and a two-hundred day moving average of $76.78. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.32 and a current ratio of 3.99.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Monday, July 29th. The medical equipment provider reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.04. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The firm had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $1 billion. During the same quarter last year, the business posted $0.93 EPS. The firm’s quarterly revenue was up 2.7% compared to the same quarter last year. On average, analysts anticipate that Hologic will post 4.09 EPS for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.